What is EyePoint Pharmaceuticals, Inc. (EYPT)?

EyePoint Pharmaceuticals, Inc. (EYPT) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of EYPT?

The current price of EYPT is $0.38. Prices are updated in real time on Stocks360.

What is EYPT's price-to-earnings (PE) ratio?

EYPT's trailing twelve-month PE ratio is -0.10, based on current price and earnings per share data available on Stocks360.

What is EYPT's market capitalization?

EYPT's market capitalization is $31,859,693.00, placing it in the small-cap tier.

EyePoint Pharmaceuticals, Inc. (EYPT)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.38

Market Cap

$31.86M

PE (TTM)

-0.10

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.68

Day Range

$0.38 – $0.42

52-wk Range

$0.36 – $19.11

Avg Volume

N/A

Volume

6.56M

EyePoint Pharmaceuticals, Inc. (EYPT) is a publicly traded company in the Healthcare sector. Latest price: $0.38. Market cap $31.86M. Trailing PE -0.10. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-30 · $12.21 2026-10-29 · $0.38 (-96.89%)

Earnings

Most Recent

Aug 5, 2026

EPS $-1.09 vs est. $-1.01

Missed by $0.08

Next Earnings

Nov 4, 2026

EPS estimate $-0.93

Proprietary Signals

Signal snapshot temporarily unavailable.

About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and develo…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.10×
P/S (TTM)	11.42×
P/B	0.20×
PEG	0.00×
P/FCF (TTM)	-0.12×
EV / EBITDA	0.19×
EV / Sales	-20.16×
Earnings Yield	-932.43%
Free Cash Flow Yield	-851.48%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$56.23M
Net Income (TTM)	-$297.07M
Free Cash Flow (TTM)	-$271.28M
Net Debt	-$88.09M
Working Capital	$146.87M
Gross Margin	41.77%
Operating Margin	-11365.22%
Net Margin	-10994.73%
Return on Equity	-135.81%
Return on Invested Capital	-167.81%